NYSE - Nasdaq Real Time Price USD

Pfizer Inc. (PFE)

Compare
28.47 -0.39 (-1.37%)
At close: 4:00 p.m. EDT
28.47 +0.00 (+0.02%)
After hours: 4:05 p.m. EDT
Advanced Chart
Loading Chart for PFE
DELL
  • Previous Close 28.86
  • Open 29.01
  • Bid 28.46 x 2200
  • Ask 28.47 x 4000
  • Day's Range 28.02 - 29.17
  • 52 Week Range 25.20 - 31.54
  • Volume 76,804,259
  • Avg. Volume 30,354,976
  • Market Cap (intraday) 161.304B
  • Beta (5Y Monthly) 0.62
  • PE Ratio (TTM) --
  • EPS (TTM) -0.46
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield 1.68 (5.82%)
  • Ex-Dividend Date Nov 8, 2024
  • 1y Target Est 33.11

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

88,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - General

Industry

More about Pfizer Inc.

Recent News: PFE

View More
View More

Related Videos: PFE

Pfizer's new R&D head will be 'essential' for growth: Analyst

As Pfizer (PFE) continues its ongoing battle with activist investor Starboard Value, Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins the Morning Brief to discuss how it may weigh on the company's outlook. The pharmaceutical giant beat third quarter earnings results with revenue growing 23% year-over-year to $17.7 billion. One of the major issues Starboard Value has been critical of is Pfizer's spending. Shibutani explains: "I think the COVID-complex revenue trajectory gave them tremendous access to resources. And with that, they were able to apply that to thinking about how to rebuild the post-COVID revenue profile for the company." Pfizer went forward with mergers and acquisitions, which had varying degrees of success. "That return on investment component is what is, I think, being questioned on terms of the overall operating expense profile," he tells Yahoo Finance. Shibutani adds, "The company has been very actively engaged in a clearly announced cost realignment program, and we're seeing those results over the last several quarters now where the operating expense levels, spending on SI&A (selling, informational, and administrative) and R&D (research and development) has come in below expectations. So it's a combination of factors here." Starboard Value has also questioned Chairman and CEO Albert Bourla's role, advocating for his replacement. Bourla recently gained the support of former Pfizer CEO Ian Read and former CFO Frank D'Amelio, according to a statement published by Guggenheim Securities earlier this month. Shibutani believes that the bigger deal is the successor Dr. Mikael Dolsten, the president of Pfizer's research and development: "At the end of the day, biopharma, the industry is driven by innovation. The point person there who can play a very important role in being a voice and strategist of defining the pipeline and the growth outlook, I think is going to be essential." Watch the video above to hear about the role of research and development when it comes to Pfizer's weight-loss drugs. Shibutani also weighs in on Pfizer's future earnings in its post-pandemic era. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Melanie Riehl
Yahoo Finance Video · 3 hrs ago
PFE
-1.37%

Performance Overview: PFE

Trailing total returns as of 2024-10-29, which may include dividends or other distributions. Benchmark is

.

YTD Return

PFE
3.31%
S&P 500
22.29%

1-Year Return

PFE
0.11%
S&P 500
41.67%

3-Year Return

PFE
25.00%
S&P 500
26.90%

5-Year Return

PFE
0.89%
S&P 500
91.91%

Compare To: PFE

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

PFE
Pfizer Inc.
28.47
-1.37%
Mkt Cap 161.304B
Industry Drug Manufacturers—General
MRK
Merck & Co., Inc.
103.79
-0.42%
Mkt Cap 263.088B
Industry Drug Manufacturers—General
JNJ
Johnson & Johnson
160.14
-0.90%
Mkt Cap 385.556B
Industry Drug Manufacturers—General
BMY
Bristol-Myers Squibb Company
52.52
-0.23%
Mkt Cap 106.479B
Industry Drug Manufacturers—General
LLY
Eli Lilly and Company
903.95
+0.93%
Mkt Cap 813.94B
Industry Drug Manufacturers—General
ABBV
AbbVie Inc.
189.48
-0.11%
Mkt Cap 334.686B
Industry Drug Manufacturers—General
GILD
Gilead Sciences, Inc.
88.08
-0.77%
Mkt Cap 109.659B
Industry Drug Manufacturers—General
NVO
Novo Nordisk A/S
112.01
-0.31%
Mkt Cap 494.643B
Industry Drug Manufacturers—General
GSK
GSK plc
38.18
+0.78%
Mkt Cap 77.858B
Industry Drug Manufacturers—General
AMGN
Amgen Inc.
316.00
-0.37%
Mkt Cap 169.796B
Industry Drug Manufacturers—General
SNY
Sanofi
53.83
-0.97%
Mkt Cap 134.96B
Industry Drug Manufacturers—General

Statistics: PFE

View More

Valuation Measures

As of 2024-10-28

  • Market Cap

    163.54B

  • Enterprise Value

    225.12B

  • Trailing P/E

    --

  • Forward P/E

    10.31

  • PEG Ratio (5yr expected)

    0.22

  • Price/Sales (ttm)

    2.96

  • Price/Book (mrq)

    1.86

  • Enterprise Value/Revenue

    4.08

  • Enterprise Value/EBITDA

    41.04

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -4.70%

  • Return on Assets (ttm)

    0.94%

  • Return on Equity (ttm)

    -2.74%

  • Revenue (ttm)

    55.17B

  • Net Income Avi to Common (ttm)

    -2.59B

  • Diluted EPS (ttm)

    -0.46

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.1B

  • Total Debt/Equity (mrq)

    79.41%

  • Levered Free Cash Flow (ttm)

    3.44B

View More

Research Analysis: PFE

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 13.28B
Earnings 41M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

27.00
33.11 Average
28.47 Current
45.00 High
 
View More

People Also Watch

JNJ Johnson & Johnson
160.14
-0.90%
 
MRK Merck & Co., Inc.
103.79
-0.42%
 
XOM Exxon Mobil Corporation
117.33
-1.32%
 
INTC Intel Corporation
22.90
-0.09%
 
JPM JPMorgan Chase & Co.
222.99
-1.11%
 
VZ Verizon Communications Inc.
41.34
-0.68%
 
WMT Walmart Inc.
81.72
-1.24%
 
CSCO Cisco Systems, Inc.
55.68
+0.72%
 
BAC Bank of America Corporation
42.53
-0.21%
 
PG The Procter & Gamble Company
167.23
-1.22%
 
GE GE Aerospace
174.09
-0.72%
 
KO The Coca-Cola Company
65.58
-1.63%
 
BMY Bristol-Myers Squibb Company
52.52
-0.23%
 
T AT&T Inc.
22.18
+0.32%
 
C Citigroup Inc.
64.69
+0.82%
 
DIS The Walt Disney Company
96.18
-0.03%